Mohamed Ibrahim Bassyouni
2020 / 4 / 30
An international study indicates that remediffer significantly reduces the time it takes COVID-19 patients to recover, compared to other treatments. Data show that remidecifer has a significant and significant effect in reducing recovery time and that patients treated with remisevir took an average of 11 days to recover, compared to 15 days for those who received another treatment.
Although the improvement was 31%, it is very important evidence that the drug can prevent the spread of this virus in the human body.
The NIAID-sponsored drug trial started on February 21 and included around 1090 participants from various locations around the world, including the United States, Germany, Denmark, Spain, Greece, and the United Kingdom. The researchers said that the so-called primary endpoint of the study was patients time to recover, more specifically "their ability to get out" of the hospital. Researchers used different measures to measure improvement, depending on the extent of the disease from the start of treatment.
I think that many countries of the world will need to adopt remdesivir soon, even if with exceptional quick approvals. The medicine, although-limit-ed in benefit for the health crisis, may be useful in expediting the solution to the economic crisis, which brings it optimism for investors and speeding up to reopen the economy.